November 10, 2026

Androlabs expands into the Gulf Region through partnership with Pharmalink

Partnership to support the distribution of Testavan® across the UAE, Saudi Arabia and Kuwait, expanding access to testosterone replacement therapy in the Gulf region.

Androlabs, the first global pharmaceutical company dedicated to men's health, announces a new distribution partnership with Pharmalink, one of the leading pharmaceutical companies in the MENA region. Under the agreement, Pharmalink will support the commercialisation and distribution of Testavan®, a testosterone replacement therapy indicated for hypogonadism in adult men, across the UAE, Kingdom of Saudi Arabia, Kuwait and the wider GCC (Gulf Cooperation Council).

The partnership marks Androlabs' entry into the Gulf region and represents a significant milestone in the company's international expansion strategy. Through Pharmalink's established commercial infrastructure and regional expertise, Androlabs aims to improve access to testosterone replacement therapy for healthcare professionals and patients across key GCC markets.

Pharmalink brings extensive capabilities to the partnership, including a team of more than 300 medical and sales representatives, in-house regulatory and pharmacovigilance expertise, and an integrated pharmacy network across the region. Its established presence and strong relationships across the healthcare sector position the company to support meaningful access to Testavan® in the Gulf.

The Gulf region represents an important growth market for men's health, with increasing focus on preventative care, healthy ageing and access to specialist treatments. Testosterone deficiency remains underdiagnosed globally, with symptoms often attributed to ageing or other health conditions, potentially delaying diagnosis and treatment. Through this partnership, Androlabs aims to make treatment more accessible to patients throughout the region.

Nicolas Vennin, Co-founder of Androlabs, commented:

“Expanding into the Gulf is an important step in Androlabs’ international growth and reflects our commitment to improving access to men's health treatments in underserved markets. Pharmalink’s strong regional expertise and established healthcare network make them an excellent partner to support the introduction of Testavan® across the Gulf region.

“As the only registered testosterone replacement therapy gel in the GCC, Testavan® will provide healthcare professionals and eligible patients with an important new treatment option for testosterone deficiency.

“We look forward to working together to ensure healthcare professionals and eligible patients have greater access to testosterone replacement therapy.”

Dr Abdul Rauf Eljbour, CEO of Pharmalink, added:

"Pharmalink is proud to partner with Androlabs to strengthen access to men's health treatment across the GCC. By combining our regional marketing and distribution expertise with Androlabs' focus on therapeutic innovation, we look forward to working with healthcare professionals to improve access to treatment for patients across the region.”

The collaboration reflects a shared commitment to advancing men's health across the Gulf through greater awareness, improved diagnosis and broader access to treatment options. As Androlabs continues its international expansion, partnerships with organisations that share its ambition to improve men's health outcomes will remain central to its growth strategy.

‍